AR072041A1 - Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos - Google Patents
Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticosInfo
- Publication number
- AR072041A1 AR072041A1 ARP080105715A ARP080105715A AR072041A1 AR 072041 A1 AR072041 A1 AR 072041A1 AR P080105715 A ARP080105715 A AR P080105715A AR P080105715 A ARP080105715 A AR P080105715A AR 072041 A1 AR072041 A1 AR 072041A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylene
- alkyl
- cycloalkyl
- trisubstituted
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
Se refiere a N-[1,3,4]-tiadiazol-2-il-bencensulfonamidas c¡clicas y a sus sales fisiologicamente aceptables y derivados fisiologicamente funcionales que muestran actividad agonista de PPARdelta o PPARdelta y PPARgamma. Los compuestos son adecuados para el tratamiento y/o prevencion de trastornos de metabolismo de cidos grasos y trastornos de utilizacion de la glucosa, as¡ como de trastornos en los que est implicada la resistencia a la insulina y la desmielinizacion y otros trastornos neurodegenerativos del sistema nervioso central y periferico. Reivindicacion 1: Compuestos de la formula (1) donde R1 es alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-O-alquilo C1-6, alquileno C0-6-O-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, en donde alquilo, alquileno, arilo, heteroarilo y cicloalquilo pueden estar no sustituidos o pueden estar mono-, di- o trisustituidos con F, CI, Br, alquilo C1-6, O-alquilo C1-6, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6; R2, R3 son, de modo independiente, H, halogeno, alquilo C1-6, alquileno C0-4-O-alquileno C0-4-H, CN, COO-alquilo C1-6, CON-alquileno C0-6-H-alquileno C0-6-H, S(O)m-alquilo C1-6, en donde alquilo y alquileno son no sustituidos o mono-, di- o trisustituidos con F; R4, R5, R6 y R7 son, de modo independiente, H, alquilo C1-6, alquileno C0-6-cicloalquilo C3-6, alquileno C0-6-arilo C6-14, alquileno C0-6-heteroarilo C5-15, alquileno C0-6-heterocicloalquilo C3-15, alquileno C0-6-heterocicloalquenilo C3-15, en donde alquilo, alquileno y cicloalquilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, alquilo C1-6, alquileno C0-6-O-alquileno C0-6-H, CF3, OCF3, CN, CO-alquilo C1-6, COO-alquilo C1-6, CON-alquileno C0-6- H-alquileno C0-6-H, S(O)m-alquilo C1-6, y en donde arilo, cicloalquilo, heterocicloalquilo, heterocicloalquenilo y heteroarilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-O-alquileno C0-4-H y en donde al menos un par de R4 y R5, R6 y R7, R5 y R6 junto con los tomos de C a los que est n conectados, o R6 junto con el tomo de C orto del anillo arom tico, forman un cicloalquilo C3-9, un heterocicloalquilo C3-9 o un heterocicloalquenilo C3-9, en donde cicloalquilo, heterocicloalquilo y heterocicloalquenilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquileno C0-4-alquileno C0-4-H; m es 0, 1, 2; en todas sus formas estereoisomericas, formas enantiomericas y mezclas en cualquier relacion, y sus sales fisiologicamente aceptables y formas tautomericas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291626 | 2007-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072041A1 true AR072041A1 (es) | 2010-08-04 |
Family
ID=39356534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105715A AR072041A1 (es) | 2007-12-26 | 2008-12-23 | Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos |
Country Status (14)
Country | Link |
---|---|
US (1) | US8344004B2 (es) |
EP (1) | EP2240474B1 (es) |
JP (1) | JP2011507914A (es) |
KR (1) | KR20100101165A (es) |
CN (1) | CN101910162A (es) |
AR (1) | AR072041A1 (es) |
AT (1) | ATE549332T1 (es) |
AU (1) | AU2008340756A1 (es) |
BR (1) | BRPI0821915A2 (es) |
CA (1) | CA2710441A1 (es) |
IL (1) | IL206531A0 (es) |
MX (1) | MX2010006647A (es) |
TW (1) | TW200940536A (es) |
WO (1) | WO2009080223A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2079734A1 (en) * | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (氮雜)吲哚-和苯並呋喃-3-磺醯胺類 |
WO2019023579A1 (en) * | 2017-07-27 | 2019-01-31 | The Mclean Hospital Corporation | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF PATHOLOGIES MEDIATED BY NURR1 AND PPARY |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
MX2021016085A (es) | 2019-06-18 | 2022-04-20 | Pfizer | Derivados de benzisoxazol sulfonamida. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3522638A1 (de) * | 1985-06-25 | 1987-01-08 | Diamalt Ag | Neue somatostatin-derivate |
JP2000511883A (ja) | 1996-04-19 | 2000-09-12 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
CA2531418A1 (en) | 2003-07-08 | 2005-01-20 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
CN101282952A (zh) | 2005-10-06 | 2008-10-08 | 塞诺菲-安万特股份有限公司 | 环状n-[1,3,4]-噻二唑-2-基-苯磺酰胺,其制备方法以及其作为药物的应用 |
AU2006299085A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
-
2008
- 2008-12-12 KR KR1020107016753A patent/KR20100101165A/ko not_active Application Discontinuation
- 2008-12-12 CA CA2710441A patent/CA2710441A1/en not_active Abandoned
- 2008-12-12 CN CN2008801232634A patent/CN101910162A/zh active Pending
- 2008-12-12 WO PCT/EP2008/010559 patent/WO2009080223A1/en active Application Filing
- 2008-12-12 JP JP2010540045A patent/JP2011507914A/ja not_active Withdrawn
- 2008-12-12 AU AU2008340756A patent/AU2008340756A1/en not_active Abandoned
- 2008-12-12 AT AT08864630T patent/ATE549332T1/de active
- 2008-12-12 MX MX2010006647A patent/MX2010006647A/es not_active Application Discontinuation
- 2008-12-12 BR BRPI0821915-0A patent/BRPI0821915A2/pt not_active IP Right Cessation
- 2008-12-12 EP EP08864630A patent/EP2240474B1/en not_active Not-in-force
- 2008-12-23 AR ARP080105715A patent/AR072041A1/es unknown
- 2008-12-24 TW TW097150346A patent/TW200940536A/zh unknown
-
2010
- 2010-06-09 US US12/796,886 patent/US8344004B2/en not_active Expired - Fee Related
- 2010-06-21 IL IL206531A patent/IL206531A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0821915A2 (pt) | 2015-06-16 |
EP2240474B1 (en) | 2012-03-14 |
CA2710441A1 (en) | 2009-07-02 |
US8344004B2 (en) | 2013-01-01 |
JP2011507914A (ja) | 2011-03-10 |
TW200940536A (en) | 2009-10-01 |
US20110224263A1 (en) | 2011-09-15 |
AU2008340756A1 (en) | 2009-07-02 |
EP2240474A1 (en) | 2010-10-20 |
KR20100101165A (ko) | 2010-09-16 |
ATE549332T1 (de) | 2012-03-15 |
WO2009080223A1 (en) | 2009-07-02 |
IL206531A0 (en) | 2010-12-30 |
MX2010006647A (es) | 2010-08-17 |
CN101910162A (zh) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072041A1 (es) | Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos | |
AR072013A1 (es) | Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas | |
AR064299A1 (es) | Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos | |
UY29830A1 (es) | Derivados de fenil-(1,2,4)-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos. | |
ECSP088322A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
AR072014A1 (es) | Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas | |
BR112015025140A2 (pt) | 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem | |
PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
UY34239A (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
ECSP066669A (es) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos | |
AR077346A1 (es) | Compuestos heterociclicos como inhibidores de janus quinasa | |
AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
CU24177B1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
AR057145A1 (es) | N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma | |
AR056121A1 (es) | 4-oxi-n- [1.3.4 -tiadiazol-2-il-bencenosulfonamidas, procesos para su preparacion y su uso como productos farmaceuticos | |
ECSP16090804A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
AR056563A1 (es) | [1,3,4]-tiadiazol-2-il-amidas biciclicas del acido aril-sulfonico, procesos para su preparacion y su uso como productos farmaceuticos | |
AR056562A1 (es) | N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma | |
EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
AR056542A1 (es) | Derivados de 2-aminotiazoles y 2-aminooxazoles procesos para su preparacion y su uso como compuestos farmaceuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |